Ying Cheng
Impact in
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
Papers in
- Oncology 270
- Lung Cancer Research Studies 120
- Colorectal Cancer Treatments and Studies 83
- Cancer Immunotherapy and Biomarkers 54
- HER2/EGFR in Cancer Research 26
-
- Lung Cancer Treatments and Mutations 192
- Lung Cancer Diagnosis and Treatment 55
- Gastric Cancer Management and Outcomes 39
- Co-authors
- Yi‐Long Wu (68 shared papers)Tony Mok (27 shared papers)Kazuhiko Nakagawa (16 shared papers)Ki Hyeong Lee (10 shared papers)Xiangdong Zhou (10 shared papers)Adam Płużański (8 shared papers)Seiji Niho (9 shared papers)Rafael Rosell (8 shared papers)
- Journals
- Journal of Clinical Oncology (78 papers)Annals of Oncology (69 papers)Journal of Thoracic Oncology (32 papers)Cancer Research (10 papers)Lung Cancer (10 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Ying Cheng
389 papers receiving 9.9k citations
Ying Cheng's Hit Papers
Peers
Comparison fields: 5 of 160
- Oncology 7.0k
- Pulmonary and Respiratory Medicine 6.1k
- Cancer Research 1.3k
- Hepatology 408
- Gastroenterology 184
Countries citing papers authored by Ying Cheng
This map shows the geographic impact of Ying Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Cheng more than expected).
Fields of papers citing papers by Ying Cheng
This network shows the impact of papers produced by Ying Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Cheng. The network helps show where Ying Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Ying Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 424 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 854 |
| 2 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2015 | 553 |
| 3 | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) Hit paper breakdown → | 2021 | 484 |
| 4 | Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial Hit paper breakdown → | 2013 | 417 |
| 5 | A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 Hit paper breakdown → | 2020 | 409 |
| 6 | Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations Hit paper breakdown → | 2018 | 331 |
| 7 | Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial Hit paper breakdown → | 2019 | 265 |
| 8 | Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study Hit paper breakdown → | 2023 | 233 |
| 9 | 2018 | 195 | |
| 10 | Metal organic frameworks as efficient adsorbents for drugs from wastewater Hit paper breakdown → | 2022 | 194 |
| 11 | 2012 | 192 | |
| 12 | 2019 | 186 | |
| 13 | 2012 | 184 | |
| 14 | 2021 | 144 | |
| 15 | 2017 | 144 | |
| 16 | 2016 | 137 | |
| 17 | Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer Hit paper breakdown → | 2023 | 130 |
| 18 | 2021 | 130 | |
| 19 | 2012 | 112 | |
| 20 | 2021 | 103 |
About Ying Cheng
Ying Cheng is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Surgery, having authored 424 papers that have together received 10.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (192 papers), Lung Cancer Research Studies (120 papers), Colorectal Cancer Treatments and Studies (83 papers), Lung Cancer Diagnosis and Treatment (55 papers), Cancer Immunotherapy and Biomarkers (54 papers), Gastric Cancer Management and Outcomes (39 papers), Neuroendocrine Tumor Research Advances (27 papers) and HER2/EGFR in Cancer Research (26 papers). The work is most often cited by research in Oncology (7.0k citations), Pulmonary and Respiratory Medicine (6.1k citations), Cancer Research (1.3k citations), Hepatology (408 citations) and Gastroenterology (184 citations). Ying Cheng has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Yi‐Long Wu, Tony Mok, Kazuhiko Nakagawa, Ki Hyeong Lee, Xiangdong Zhou, Adam Płużański, Seiji Niho, Rafael Rosell, Maria Rita Migliorino and Shukui Qin. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Cancer Research and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.